Hao Desirée, Phan Tien, Jagdis Amanda, Siever Jodi E, Klimowicz Alexander C, Laskin Janessa J, Thomson Thomas A, Rose M Sarah, Petrillo Stephanie K, Magliocco Anthony M, Lau Harold Y
.
Clin Invest Med. 2014 Oct 4;37(5):E320-30. doi: 10.25011/cim.v37i5.22012.
Aberrant expression of proteins involved in epithelial-to-mesenchymal transition have been described in various cancers. In this retrospective study, we sought to evaluate E-cadherin, β-catenin and vimentin protein expression in non-metastatic nasopharyngeal (NPC) patients treated with curative intent, examine their relationship with each other, and with clinical outcome measures.
Pre-treatment formalin-fixed paraffin-embedded biopsies of 140 patients treated between January 2000 and December 2007 were assembled into a tissue microarray (TMA). Automated quantitative immunohistochemistry (AQUA®) was performed on sequential TMA sections stained with fluorescent-labeled antibodies against E-cadherin, β-catenin and vimentin. Cox proportional hazards regression was used to estimate the effect of cytoplasmic vimentin, cytoplasmic E-cadherin, β-catenin nuclear/cytoplasmic ratio expression on overall survival and disease-free survival.
The average age of the patients was 51.7 years (SD=12.1; range 18-85), 66% were male, 71% had a KPS ≥ 90% at the start of treatment and 65% had stage III/IV disease. After adjusting for performance status, WHO and stage, high E-cadherin levels over the 75th percentile were found to produce a significantly increased risk for both a worse overall survival (HR = 2.53, 95% CI 1.21, 5.27) and disease free survival (DFS; HR = 2.14, 95%CI 1.28, 3.59). Vimentin levels over the first quartile produced an increased risk for a worse DFS (HR = 2.21, 95% CI 1.11, 4.38). No association was seen between β-catenin and survival.
In this cohort of NPC patients, higher levels of E-cadherin and higher levels of vimentin were associated with worse outcomes. Further work is needed to understand the role of these epithelial mesenchymal transition proteins in NPC.
上皮-间质转化相关蛋白的异常表达已在多种癌症中被描述。在这项回顾性研究中,我们试图评估接受根治性治疗的非转移性鼻咽癌(NPC)患者中E-钙黏蛋白、β-连环蛋白和波形蛋白的蛋白表达,研究它们之间的相互关系以及与临床结局指标的关系。
收集2000年1月至2007年12月期间接受治疗的140例患者的治疗前福尔马林固定石蜡包埋活检组织,制成组织芯片(TMA)。对TMA连续切片进行自动定量免疫组织化学(AQUA®)检测,用荧光标记抗体检测E-钙黏蛋白、β-连环蛋白和波形蛋白。采用Cox比例风险回归分析评估细胞质波形蛋白、细胞质E-钙黏蛋白、β-连环蛋白核/质比表达对总生存和无病生存的影响。
患者的平均年龄为51.7岁(标准差=12.1;范围18-85岁),66%为男性,71%在治疗开始时KPS≥90%,65%为III/IV期疾病。在调整了体能状态、世界卫生组织(WHO)分期后,发现E-钙黏蛋白水平高于第75百分位数会显著增加总生存较差(HR=2.53,95%CI 1.21,5.27)和无病生存(DFS;HR=2.14,95%CI 1.28,3.59)的风险。波形蛋白水平高于第一四分位数会增加DFS较差的风险(HR=2.21,95%CI 1.11,4.38)。未发现β-连环蛋白与生存之间存在关联。
在这组NPC患者中,较高水平的E-钙黏蛋白和较高水平的波形蛋白与较差的结局相关。需要进一步开展工作以了解这些上皮间质转化蛋白在NPC中的作用。